Danaher Corporation, a global leader in science and technology innovation, announced a strategic collaboration with AstraZeneca aimed at developing and commercializing cutting-edge diagnostic tools designed to optimize the use of precision medicine. This initiative marks a significant step toward enabling more tailored treatment approaches and improving patient outcomes across a range of therapeutic areas.
“Precision medicines are more targeted than standard therapies and thus require precision diagnostics to determine which patients are most likely to benefit,” said Julie Sawyer Montgomery, Danaher Executive Vice President. “We are excited to work with AstraZeneca on the goal of creating novel tests to increase access to precision medicines, helping ensure that no patients are left behind.”
The collaboration will be anchored by Danaher’s newly launched Centers for Enabling Precision Medicine, which provide a streamlined, end-to-end infrastructure for diagnostic development. Leveraging the expertise of Leica Biosystems, a Danaher operating company, the partnership will initially focus on the creation of digital and computational pathology tools. These include AI-powered algorithms aimed at enhancing diagnostic accuracy and assisting clinicians in identifying patients most likely to benefit from highly targeted treatments.
Also Read: Sanofi completes acquisition of Dren Bio’s DR-0201
“The transformative potential of next-wave precision medicines such as antibody-drug conjugates will depend on our ability to identify the patients most likely to benefit from them,” said Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca. “Our partnership with Danaher and Leica Biosystems underscores our commitment to pioneering AI-based diagnostics which can improve patient selection, and our belief that collaboration is a critical accelerant for such progress.”